TY - JOUR
T1 - Impact of Renal Disease on Patients with Hepatitis C
T2 - A Retrospective Analysis of Disease Burden, Clinical Outcomes, and Health Care Utilization and Cost
AU - Solid, Craig A.
AU - Peter, Senaka A.
AU - Natwick, Tanya
AU - Guo, Haifeng
AU - Collins, Allan J.
AU - Arduino, Jean Marie
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Background/Aims: Few studies explore the magnitude of the disease burden and health care utilization imposed by renal disease among patients with hepatitis C virus (HCV). We aimed to describe the characteristics, outcomes, and health care utilization and costs of patients with HCV with and without renal impairment. Methods: This retrospective analysis used 2 administrative claims databases: the US commercially insured population in Truven Health MarketScan® data (aged 20-64 years), and the US Medicare fee-for-service population in the Medicare 20% sample (aged ≥65 years). Baseline characteristics and comorbid conditions were identified from claims during 2011; patients were followed for up to 1 year (beginning January 1, 2012) to identify health outcomes of interest and health care utilization and costs. Results: In the MarketScan and Medicare databases, 35,965 and 10,608 patients with HCV were identified, 8.5 and 26.5% with evidence of renal disease (chronic kidney disease [CKD] or end-stage renal disease [ESRD]). Most comorbid conditions and unadjusted outcome rates increased across groups from patients with no evidence of renal disease to non-ESRD CKD to ESRD. Health care utilization followed a similar pattern, as did the costs. Conclusions: Our findings suggest that HCV patients with concurrent renal disease have significantly more comorbidity, a higher likelihood of negative health outcomes, and higher health care utilization and costs.
AB - Background/Aims: Few studies explore the magnitude of the disease burden and health care utilization imposed by renal disease among patients with hepatitis C virus (HCV). We aimed to describe the characteristics, outcomes, and health care utilization and costs of patients with HCV with and without renal impairment. Methods: This retrospective analysis used 2 administrative claims databases: the US commercially insured population in Truven Health MarketScan® data (aged 20-64 years), and the US Medicare fee-for-service population in the Medicare 20% sample (aged ≥65 years). Baseline characteristics and comorbid conditions were identified from claims during 2011; patients were followed for up to 1 year (beginning January 1, 2012) to identify health outcomes of interest and health care utilization and costs. Results: In the MarketScan and Medicare databases, 35,965 and 10,608 patients with HCV were identified, 8.5 and 26.5% with evidence of renal disease (chronic kidney disease [CKD] or end-stage renal disease [ESRD]). Most comorbid conditions and unadjusted outcome rates increased across groups from patients with no evidence of renal disease to non-ESRD CKD to ESRD. Health care utilization followed a similar pattern, as did the costs. Conclusions: Our findings suggest that HCV patients with concurrent renal disease have significantly more comorbidity, a higher likelihood of negative health outcomes, and higher health care utilization and costs.
KW - Chronic kidney disease
KW - End-stage renal disease
KW - Health care utilization
KW - Hepatitis C virus
KW - Outcomes
UR - http://www.scopus.com/inward/record.url?scp=85013637261&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013637261&partnerID=8YFLogxK
U2 - 10.1159/000454684
DO - 10.1159/000454684
M3 - Article
C2 - 28214902
AN - SCOPUS:85013637261
SN - 1660-8151
VL - 136
SP - 54
EP - 61
JO - Nephron
JF - Nephron
IS - 2
ER -